The instruction for medical use
of Imudon Torgovoye medicine a name
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
of the Tablet for resorption
One tablet contains:
active agent – Imudon (mix of lysates of bacteria) * 2.70 mg (in terms of dry matter),
excipients: glycine, lactoses monohydrate, Mannitolum, povidone, sodium saccharinate, Natrii hydrocarbonas, citric acid anhydrous, magnesium stearate, fragrance mint (essential oil of a peppermint and the Arabian gum)
* – Lysates of bacteria – 0.1575 ** mg)
(Lactobacillus acidophilus Lactobacillus helveticus Lactobacillus delbrueckii ss lactis Lactobacillus fermentum Streptococcus pyogenes groupe A Enterococcus faecium Enterococcus faecalis Streptococcus sangius groupe H Staphylococcus aureus Klebsiella pneumoniae ss pneumoniae Corynebacterium pseudodiphtheriticum Fusobacterium nucleautum ss fusiforme Candida albicans)
Glycine – 2.00 ** mg)
Sodium dezoksikholat – 0.53 ** mg)
Tiomersal – no more than 0.0125 ** mg).
** – the estimated quantity
of the Tablet of white or almost white color, a ploskotsilindrichesky form, with a smooth brilliant surface, with slanted edges, with a mint smell, is allowed insignificant marbling.
Dental drugs. Antimicrobial drugs for topical treatment of diseases of an oral cavity. Other.
The ATX A01AB11 code
Pharmacokinetics Drug properties mainly works in an oral cavity, now there are no data on system absorption.
Imudon’s pharmacodynamics represents a polyvalent antigenic complex mix of lysates of bacteria which composition corresponds to the activators which are the most often causing inflammatory processes in an oral cavity and a throat.
Imudon activates phagocytosis, promotes increase in quantity of immunocompetent cells, increases production of lysozyme and interferon, secretory immunoglobulin A in saliva.
Adjuvant treatment of the infectious diseases limited to an oral cavity including cankers:
periodontosis, a periodontal disease, stomatitis, a glossitis, herpetic stomatitis
the infectious and inflammatory diseases of a mouth and throat
oral cavity dysbacteriosis
an adenoid disease
of an injury of a mucous membrane of an oral cavity caused by dentures
infectious complications after exodontia implantation of teeth
preoperative preparation and the postoperative period of tonsilectomy
the Route of administration and doses
of the Tablet are intended for topical administration, rassasyvat them in an oral
cavity, without chewing and without washing down with water.
The daily dose makes from 6 to 8 tablets.
From 6 to 14 years daily dose of 6 tablets.
Duration of a course of treatment is from 6 to 8 days.
of These clinical trials it is not enough to determine the frequency of side reactions at the Imudon drug treatment. Side effects about which it was reported from post-marketing practice are given below. Frequency cannot be determined.
reactions of hypersensitivity (rash, urticaria, Quincke’s disease), erythema, eczema
nausea, vomiting, abdominal pain, diarrhea
inexplicable fervescence higher than 39 With in the early period of treatment, a nasopharyngitis, sinusitis, laryngitis, bronchitis, an attack of asthma and the isolated cough
a knotty erythema, thrombocytopenia
a hemorrhagic vasculitis
of the Contraindication
– the increased individual sensitivity to drug or its components
– children’s age up to 6 years, because of possible wrong use (ingestion or chewing)
– presence of autoimmune diseases
– pregnancy and the period of a lactation
– persons with hereditary intolerance of a galactose, deficiency of Lappa lactase, glucose galactose malabsorption
Imudon can accept Medicinal interactions with medicines of other groups.
of the Indication do not assume long use of drug. If symptoms remain more than 8 days and are not followed by temperature increase, it is necessary to reconsider treatment.
As Imudon contains lactose, he is contraindicated to persons with rare congenital diseases as a syndrome of congenital malabsorption of glucose and a galactose or deficiency of lactase. Carefully sick with diabetes.
The patient should be informed on fervescence possible in rare instances higher than 39 With for no apparent reason. At the first signs of such symptom it is necessary to stop treatment immediately. However it is necessary to distinguish such fervescence from the symptomatic, tied with diseases ENT organs.
At patients with bronchial asthma cases of asthmatic attacks when using drugs of bacterial lysates for the purpose of immunostimulation were described. At development of an asthmatic attack it is not recommended to continue treatment.
In case of need the mouth should be rinsed not earlier than in 1 hour after drug Imudon use not to reduce therapeutic activity of drug. When prescribing drug the patients keeping to a saltless or low-salt diet need to consider that 1 tablet of the drug Imudon contains 15 mg of sodium. Because of Mannitolum content perhaps moderate aperient action.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not exist the data confirming need of any restrictions during treatment for the activity connected with driving or other mechanisms.
it is not revealed
the Form of release and packing
On 8 tablets place in blister strip packaging from composition material polyamide/aluminium/polyvinylchloride (Amcor Flexibles Singen GmbH, Germany or Constantia Hueck Folien GmbH & Co. KG, Germany) and the printing aluminum foil varnished or productions Amcor Flexibles Singen GmbH, Germany.
On 3 or 5 blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard of brand A or chrome ersatz.
To Store storage conditions at
a temperature not higher than 25 S. Hranit out of children’s reach!
not to apply a period of storage after an expiration date.
of JSC Pharmstandard-Tomskkhimpharm,
Russia, 634009, Tomsk, Lenin Ave, 211,
ph./fax (3822) 40-28-56, www.pharmstd.ru
the Name and the country of the holder of the registration certificate
of JSC Pharmstandard-Tomskkhimpharm, Russia
the Name, the address and a contact information of the organization in the territory of the Republic of Kazakhstan: the accepting claim (offer) on quality of medicines from consumers, responsible for post-registration observation of safety of medicine
of Karagandinsky LLP a pharmaceutical complex,
100009, Republic of Kazakhstan, Karaganda, Gazaliyev St., building 16.
ph./fax: +7 (7212) 437002
ph.: + 7 (7212) 507322